Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.38 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.38 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.38 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265376 | 0.83 | ALDH1A1 (0.47) | KCNH2CYP1A2CYP2D6ALDH1A1POLB | |
| SCHEMBL9096133 | 0.78 | KCNH2 (0.57) | KCNH2NOS1DHFRCYP2D6BACE1 | |
| SCHEMBL752089 | 0.78 | KCNH2 (0.57) | KCNH2NOS1DHFRKDM4ECYP1A2 | |
| SCHEMBL5258991 | 0.77 | FFAR1 (0.36) | KCNH2DHFRCCNCCDK8CYP1A2 | |
| SCHEMBL2013407 | 0.75 | FFAR1 (0.32) | KCNH2FFAR1MAPTSMN1; SMN2 | |
| SCHEMBL27621059 | 0.75 | FFAR1 (0.32) | KCNH2FFAR1 | |
| SCHEMBL2018150 | 0.75 | RECQL (0.35) | KCNH2FFAR1 | |
| SCHEMBL5674666 | 0.74 | KCNH2 (0.52) | KCNH2NOS1ESR1ESR2BACE1 | |
| SCHEMBL17820575 | 0.74 | — | — | |
| SCHEMBL990352 | 0.74 | KCNH2 (0.52) | KCNH2NOS1CYP1A2CYP2D6FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562883-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | NOGRA PHARMA LIMITED (IE) | 2020-02-18 | — | — | US | disclosed |
| US-10208017-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | NOGRA PHARMA LIMITED (IE) | 2019-02-19 | — | — | US | disclosed |
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2016-07-07 | — | — | US | disclosed |
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | ICOS, NFATC1, CD74 | KCNH2 3811/4885NOS1 2111/4885DHFR 123/4885 |
| US-10562883-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | ICOS, NFATC1, CD74 | KCNH2 3811/4885NOS1 2111/4885DHFR 123/4885 |
| US-10208017-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | ICOS, NFATC1, CD74 | KCNH2 3811/4885NOS1 2111/4885DHFR 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.